Clinical Trial Search

Primary: Percent Change From Baseline in LDL-C at Week 12 — -16.03; -4.98 Percent Change — p=0.0057

Primary: Clinical Effectiveness in Generalised Anxiety Disorder Measured by at Least a 5 Point Reduction in Scores on the GAD-7 — 102 Participants

Primary: Percent Change From Baseline to End of Study (EOS) in Fasting Serum Triglycerides (TG) — -47.32; -32.95; -27.30 Percent Change — p=0.0063

Primary: Trough Serum Concentration (Ctrough) of Pertuzumab During Cycle 7 (Pre-Dose Cycle 8) — 72.4; 88.7 micrograms per millilitre (μg/mL)

Primary: Combined Outcome of Death or Bronchopulmonary Dysplasia — 125; 137 Participants

Primary: Complete Spontaneous Bowel Movement (CSBM) Response — 47; 56 Participants — p=0.016

Primary: Number of Participants With Radiographic Recurrence at 12 Months — 3 Participants

Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 3; 0 Participants

Primary: Objective Response Rate (ORR) Based on International Working Group (IWG) Response Assessment Criteria Per Independent Central Review — 45.3; 13.0 Percentage of…

Primary: Flow-mediated Dilation (FMD) Percentage — 7.61; 8.27; 7.31 percentage of baseline dilation — p=0.88

Primary: Number of Participants With Adverse Drug Reactions (ADRs) Treated — 30 Participants

Primary: Percentage of Responders at Week 6 — 100; 88.9; 88.9 percentage of subjects — p=0.1664

Primary: Visual Analogue Scale (VAS) Scores at Baseline and Post Treatment — 68.56; 69.03; 25.34; 25.78 score on a scale

Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ixekizumab — 6.31; 6.29; 6.50 microgram/milliliter (ug/mL)

Primary: Change in Patient Management — 6; 15; 21; 21 Participants